Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (CrossMab) is designed to be expressed as four chains with knobs-into-holes mutations and domain crossover. After one or multi-steps purification, high-purity antibody can be obtained. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (CrossMab) (CROSSAB-098). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS